Active substance
Results for the substance tremelimumab
1 result
About this active substance
Tremelimumab is a humanized monoclonal antibody targeting the CTLA-4 protein (cytotoxic T-lymphocyte-associated antigen 4), used in the treatment of certain cancers, including advanced melanoma and hepatocellular carcinoma. It works by blocking CTLA-4, a molecule that inhibits T-cell activation, thereby enhancing the immune response against tumor cells.
Tremelimumab is administered intravenously, often in combination with other immunotherapies such as durvalumab, to enhance treatment efficacy. The dose and frequency of administration are adjusted based on the type of cancer and patient response.
Common side effects include fatigue, diarrhea, skin rashes, and itching. In rare cases, severe adverse reactions such as colitis, autoimmune hepatitis, or endocrinopathies may occur. Careful monitoring of the patient is essential to promptly identify and manage these reactions.
Tremelimumab represents an innovative option in cancer immunotherapy, offering patients with advanced tumors a chance for prolonged survival and improved quality of life.
Tremelimumab is administered intravenously, often in combination with other immunotherapies such as durvalumab, to enhance treatment efficacy. The dose and frequency of administration are adjusted based on the type of cancer and patient response.
Common side effects include fatigue, diarrhea, skin rashes, and itching. In rare cases, severe adverse reactions such as colitis, autoimmune hepatitis, or endocrinopathies may occur. Careful monitoring of the patient is essential to promptly identify and manage these reactions.
Tremelimumab represents an innovative option in cancer immunotherapy, offering patients with advanced tumors a chance for prolonged survival and improved quality of life.